Key Takeaways Viking Therapeutics’ VK2735 oral pill achieved 12.2% weight loss in mid-stage trials, below the 15% benchmark investors anticipated. Gastrointestinal side effects led to high discontinuation rates, undermining enthusiasm...
Key Takeaways President Trump’s strategy favours direct Russia-Ukraine negotiations without a ceasefire, aligning with Russian preferences and potentially reshaping market expectations. Energy markets may see sustained volatility due to supply...
Key Takeaways Lemonade has scaled rapidly post-IPO, with in-force premium up 408% and customer growth of 169% since 2020. The company’s AI-driven underwriting model has improved efficiency, contributing to a...
Key Takeaways Ford projects a $2 billion financial impact from tariffs in 2025, highlighting vulnerabilities even for domestically anchored manufacturers. The company’s Q2 2025 results included $800 million in tariff-related...
Key Takeaways The Trade Desk is targeting sustained high-teens revenue growth, with projections implying a 13.7% annualised return if margin improvements are achieved. Despite a share price significantly below its...
Key Takeaways The FDA has approved Novo Nordisk’s Wegovy for treating MASH in adults with moderate to advanced liver fibrosis, expanding its indications beyond obesity and cardiovascular health. Clinical trials...
Key Takeaways Doximity achieved a Rule of 40 score of 56, underpinned by 15% year-over-year revenue growth and a 41% free cash flow margin in Q1 FY2026. The company’s vertically...
Key Takeaways Palantir prioritises hands-on impact and performance over traditional academic qualifications, positioning employment at the firm as a modern credential. The company’s Meritocracy Fellowship invites top-performing school leavers into...
Key Takeaways UnitedHealth Group is trading at a forward P/E of 8.75 despite a market cap of $237 billion, attracting institutional investors seeking long-term value. Analysts project over $25 billion...
Key Takeaways Insider buying at Eli Lilly surged as share prices dipped near 52-week lows, signalling executive confidence in the company’s future performance. Shares have declined approximately 17% from their...
